Amlodipine besylate 10 mg picture
Pro Research Analysisby 
Searched over 200M research papers
Amlodipine Besylate 10 mg: Pharmacokinetics, Bioequivalence, and Clinical Applications
Introduction to Amlodipine Besylate 10 mg
Amlodipine besylate is a widely used calcium channel blocker prescribed for the treatment of hypertension and angina. It is available in various formulations, including a 10 mg tablet, which is commonly prescribed for its efficacy in managing blood pressure and cardiovascular conditions.
Pharmacokinetics of Amlodipine Besylate 10 mg
The pharmacokinetics of amlodipine besylate have been extensively studied. A single 10 mg dose of amlodipine besylate exhibits a mean peak plasma concentration (C_max) of approximately 8.19 µg/L, with a time to reach peak concentration (T_max) of around 5.60 hours. The drug has a long half-life (t_1/2) of approximately 35.4 hours, which supports its once-daily dosing regimen. These pharmacokinetic properties ensure a sustained therapeutic effect, making it a reliable option for long-term management of hypertension.
Bioequivalence Studies of Amlodipine Besylate
Comparative Studies with Other Amlodipine Salts
Several studies have compared the bioequivalence of amlodipine besylate with other amlodipine salts, such as amlodipine maleate and amlodipine orotate. These studies have consistently shown that different salts of amlodipine, including besylate, exhibit similar pharmacokinetic profiles and are bioequivalent . This indicates that the therapeutic effects of amlodipine are primarily due to the active molecule itself, rather than the specific salt form.
Bioequivalence with Branded Formulations
Research has also focused on comparing generic formulations of amlodipine besylate with established branded versions. For instance, a study conducted in healthy Chinese male volunteers demonstrated that a newly developed dispersible tablet of amlodipine besylate was bioequivalent to a branded formulation, with similar C_max, AUC (area under the curve), and T_max values. Another study in Sudan confirmed the bioequivalence of three generic brands of amlodipine besylate 10 mg tablets with the innovator brand, meeting the World Health Organization (WHO) criteria for biowaiver.
Clinical Applications and Tolerability
Efficacy in Hypertension Management
Amlodipine besylate has been proven effective in lowering blood pressure in patients with mild to moderate hypertension. In a phase III clinical trial involving Korean adults, both amlodipine camsylate and amlodipine besylate significantly reduced systolic and diastolic blood pressure, with no significant differences between the two formulations. This underscores the drug's efficacy and versatility in managing hypertension across different populations.
Combination Therapies
Amlodipine besylate is often used in combination with other antihypertensive agents to enhance therapeutic outcomes. For example, fixed-dose combinations of amlodipine besylate with olmesartan medoxomil have been shown to be bioequivalent to the individual components administered separately, providing a convenient and effective treatment option for patients with hypertension. Additionally, a single-pill combination of amlodipine besylate and atorvastatin calcium has been developed to simultaneously manage blood pressure and lipid levels, improving patient adherence and reducing cardiovascular events.
Conclusion
Amlodipine besylate 10 mg is a well-established medication for the treatment of hypertension and angina, with robust pharmacokinetic properties and proven bioequivalence across various formulations and brands. Its efficacy in lowering blood pressure, combined with its versatility in combination therapies, makes it a cornerstone in cardiovascular disease management. The consistent findings across multiple studies highlight its reliability and safety, ensuring its continued use in clinical practice.
Sources and full results
Most relevant research papers on this topic